CVS Health (CVS) awards stock options and RSUs to its Chief Medical Officer

Filing Impact

(Very High)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

CVS Health reported that EVP and Chief Medical Officer Amy Compton-Phillips received equity compensation awards. She was granted stock options for 35,928 shares of common stock at an exercise price of $71.82 per share, expiring on March 31, 2036. These options become exercisable in three equal annual installments starting March 31, 2027. She also received 5,569 restricted stock units (RSUs) under the 2017 Incentive Compensation Plan, which vest in three equal installments beginning March 31, 2027. Following these grants, she directly holds 58,660 shares of CVS common stock. These awards are grants, not open-market purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Compton-Phillips Amy

Role EVP, Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	35,928	$71.82	$2.58M
Grant/Award	Common Stock (RSUs)	5,569	$71.82	$400K

Holdings After Transaction: Stock Option — 35,928 shares (Direct); Common Stock (RSUs) — 58,660 shares (Direct)

Footnotes (1)

Consists of restricted stock units awarded pursuant to Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in three equal installments, commencing 3/31/2027. Option becomes exercisable in three equal annual installments, commencing 3/31/2027.

Key Figures

Stock options granted: 35,928 options Option exercise price: $71.82 per share Option expiration: March 31, 2036 +3 more

6 metrics

Stock options granted 35,928 options Grant on March 31, 2026 at $71.82 exercise price

Option exercise price $71.82 per share Exercise price for 35,928 stock options

Option expiration March 31, 2036 Expiration date of granted stock options

RSUs granted 5,569 RSUs Restricted stock units awarded March 31, 2026

RSU vesting start March 31, 2027 Restrictions lapse in three equal installments from this date

Shares after grant 58,660 shares Common stock directly owned following RSU award

Key Terms

restricted stock units, 2017 Incentive Compensation Plan, exercisable, annual installments, +1 more

5 terms

restricted stock units financial

"Consists of restricted stock units awarded pursuant to Issuer's 2017 Incentive Compensation Plan."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2017 Incentive Compensation Plan financial

"Consists of restricted stock units awarded pursuant to Issuer's 2017 Incentive Compensation Plan."

exercisable financial

"Option becomes exercisable in three equal annual installments, commencing 3/31/2027."

annual installments financial

"Option becomes exercisable in three equal annual installments, commencing 3/31/2027."

expiration date financial

"expiration_date": "2036-03-31T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

04/02/2026 - 04:52 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Compton-Phillips Amy

(Last)

(First)

(Middle)

ONE CVS DRIVE

(Street)

WOONSOCKET

RHODE ISLAND

02895

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CVS HEALTH Corp [ CVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock (RSUs)	03/31/2026		A⁽¹⁾		5,569	A	$71.82	58,660	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option⁽²⁾	$71.82	03/31/2026		A		35,928		03/31/2027	03/31/2036	Common Stock	35,928	$71.82	35,928	D

Explanation of Responses:

1. Consists of restricted stock units awarded pursuant to Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in three equal installments, commencing 3/31/2027.

2. Option becomes exercisable in three equal annual installments, commencing 3/31/2027.

	/s/ Amy Compton-Phillips	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did CVS (CVS) grant to Amy Compton-Phillips?

CVS granted Amy Compton-Phillips stock options on 35,928 shares at $71.82 and 5,569 restricted stock units. Both awards are compensation-related grants under company plans, not open-market trades, and provide long-term equity incentives tied to CVS common stock performance.

How do the new stock options for CVS (CVS) CMO vest and when do they expire?

The stock options become exercisable in three equal annual installments starting March 31, 2027. They have an exercise price of $71.82 per share and expire on March 31, 2036, giving the executive a long-term window to exercise the options if conditions are met.

What are the vesting terms of the RSUs granted by CVS (CVS) to its CMO?

The 5,569 restricted stock units were awarded under CVS’s 2017 Incentive Compensation Plan. Restrictions on these RSUs lapse in three equal installments beginning March 31, 2027, meaning shares will deliver over time as vesting milestones are reached under the plan.

How many CVS (CVS) shares does Amy Compton-Phillips hold after these transactions?

After the RSU grant, Amy Compton-Phillips directly holds 58,660 shares of CVS common stock. This figure reflects her post-transaction share balance as reported, combining existing holdings with the newly awarded restricted stock units credited to her account.

Are Amy Compton-Phillips’ CVS (CVS) Form 4 transactions open-market buys or sells?

The reported transactions are equity compensation grants, not open-market buys or sells. Both the stock options and restricted stock units were acquired under company incentive plans, classified as “grant, award, or other acquisition” rather than discretionary market trading activity.